secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001558370-23-003639
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios posts FY2022 net loss $12.2M; cash $7.0M; FDA meeting on IMC-1 Phase 3 in March
--------------------------------------------------------------------------------

- Net loss Q4 2022 $2.0M ($0.11/share) vs $4.5M in Q4 2021; FY2022 net loss $12.2M ($1.11) vs $16.0M in FY2021.
- Cash $7.0M at Dec 31, 2022; expects funding through mid-2024 for current ops but needs additional funds for IMC-1 FM trials.
- End-of-Phase 2 meeting with FDA in March 2023 to discuss IMC-1 progression into Phase 3 development.
- Patient enrollment complete for exploratory Long-COVID study; top-line results expected mid-2023.
- R&D expenses decreased to $1.3M in Q4 2022 vs $2.9M in Q4 2021; FY2022 R&D $8.1M vs $10.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023003639/0001558370-23-003639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023003639/tmb-20230314x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer